MYGN logo

MYGN
Myriad Genetics, Inc.

2,124
Mkt Cap
$360.79M
Volume
1.03M
52W High
$8.59
52W Low
$3.53
PE Ratio
-0.89
MYGN Fundamentals
Price
$3.82
Prev Close
$3.91
Open
$3.88
50D MA
$4.52
Beta
1.19
Avg. Volume
997,709.24
EPS (Annual)
-$3.95
P/B
1.07
Rev/Employee
$305,370.37
$629.69
Loading...
Loading...
News
all
press releases
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
Myriad (MYGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
News Placeholder
More News
News Placeholder
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock...
News Placeholder
TD Cowen Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00
TD Cowen decreased their target price on Myriad Genetics from $7.00 to $6.00 and set a "hold" rating for the company in a research note on Wednesday...
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Given New $5.50 Price Target at Wells Fargo & Company
Wells Fargo & Company dropped their target price on Myriad Genetics from $6.00 to $5.50 and set an "equal weight" rating for the company in a report on Wednesday...
News Placeholder
Myriad Genetics Q1 Earnings Call Highlights
Myriad Genetics (NASDAQ:MYGN) reported first-quarter fiscal 2026 revenue of $200.4 million, reflecting 2% year-over-year growth and landing within the company's prior guidance range. Management highlighted continued momentum in hereditary cancer testing and GeneSight, partially offset by a year-over...
News Placeholder
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Myriad Genetics (NASDAQ:MYGN - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). The company had revenue of $200.40 million during the quarter...
News Placeholder
Myriad Genetics Q1 Loss Widens
(RTTNews) - Myriad Genetics, Inc. (MYGN) on Tuesday reported first-quarter results with revenue rising slightly from last year, while losses widened compared to the prior period...
News Placeholder
Myriad Genetics (MYGN) to Release Quarterly Earnings on Tuesday
Myriad Genetics (NASDAQ:MYGN) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-myriad-genetics-inc-stock...
News Placeholder
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available